Introduction
To determine if insulin analogues are beneficial when treating patients with type 2 diabetes (T2D), the A 1 chieve â study was conducted as a 6-month prospective, multinational (28 countries), open-labelled, observational study. The study enrolled 66,726 patients with T2D, both insulin and non-insulin users who were started on detemir, aspart or biphasic aspart 30. The study results showed that insulin analogue therapy was associated with marked improvements in glycemic, blood pressure and lipid control without increasing hypoglycaemic rates or body weight (1) . In the A 1 chieve â study conducted in Korea, the treatment with insulin analogues showed beneficial 24-week reductions in HbA 1c , fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) (À1.6 AE 2.2%, À2.5 AE 4.7 and À4.0 AE 6.4 mmol/l, respectively). In addition, the overall quality of life score was improved, while no major hypoglycaemic episodes were observed and the rate of minor hypoglycaemic episodes marginally decreased (2) . Although the A 1 chieve â study in Korea demonstrated the benefits of insulin analogues, individualised recommendations regarding the optimal approach to insulin analogue therapy was not provided, including types of insulin formulation [basal, rapid-acting (henceforth bolus), basal and bolus and biphasic insulin] and insulin regimen (starting doses, number of injections). In addition, few reports exist regarding the characteristics of Korean patients with T2D who respond adequately to insulin analogue therapy (3) (4) (5) . Therefore, in this sub-analysis from the A 1 chieve â study, we compared the glucose-lowering effectiveness of insulin analogues and their combination according to baseline glycemic status in Korean patients with T2D.
Patients and methods

Patients and study design
The study population and design were described in a previous report (2) . Briefly, Korean patients with T2D, including those who were started on biphasic aspart 30, detemir or aspart within the 4 weeks prior to the initiation of the study were eligible to participate in the study. Patients with a hypersensitivity to the study products or women who were pregnant, breast feeding or had the intention of becoming pregnant within the next 6 months were excluded from the A 1 chieve â study. The cessation of study insulin was at the discretion of the patients' physician, who also determined all subsequent treatments (aspart, biphasic aspart 30, or detemir) according to standard protocol. Patients were allowed to withdraw from the study at any time. The protocol was reviewed and approved by independent Institutional Review Boards in the study sites and all participants gave written informed consent before any trialrelated activity. 
Results
Baseline characteristics according to baseline HbA 1c levels
Of the 4058 patients who were exposed to the selected insulin at least once and constituted the full analysis set (FAS), 3074 patients had their HbA 1c level measured at the baseline and final visit and 2952 patients (72.7% of FAS) who used one of four insulin analogue regimens were eligible for analysis ( Figure 1 ). Baseline characteristics of the study patients according to baseline HbA1 levels are shown in Table 1 . Patients were allocated to group I (HbA 1c < 7.5%, n = 302, 173 males, 129 females), group II (7.5% ≤ HbA 1c < 9.0%, n = 877, 449 males, 428 females) or group III (≥ 9.0%, n = 1895, 1049 males, 846 females). The duration of diabetes was significantly longer in group II (10.0 years, 11.4 years and 9.3 years in groups I, II and III, respectively; p < 0.001). In addition, body mass index (BMI) was statistically different between groups (24.0, 24.6 and 24.2 kg/m 2 , groups I, II and III, respectively; p = 0.016). Glucose-lowering effectiveness according to baseline HbA 1c levels
In a previous A 1 chieve â study report in Korea (2), HbA 1c decreased from 9.7% at baseline to 8.1% at the 24-week end-point, resulting in a significant reduction of 1.6 AE 2.2% (p < 0.001). In addition, the proportion of patients who achieved the target HbA 1c level of < 7.0% increased from 4.8% at baseline to 18.1% at the 12-week interim and 22.7% at the 24-week end-point. In terms of type and regimen of insulin analogues, mean HbA 1c reduction was the greatest in patients on a basal-bolus regimen (levemir and aspart, 2.2 AE 2.5%; p < 0.001) and lowest in patients on a bolus regimen (aspart, 0.7 AE 2.3%; p = 0.036).
In the first step of this study analysis, we classified patients into three groups according to baseline HbA 1c levels. Table 2 shows the glucose-lowering effectiveness of insulin analogues according to baseline HbA 1c levels. Baseline mean HbA 1c levels were 6.8%, 8.3% and 11.0% in group I (HbA 1c < 7.5%), II (7.5 ≤ HbA 1c < 9.0%) and III (HbA 1c > 9.0%), respectively. For Korean patients with relatively well controlled (group I, HbA 1c < 7.5%) and poorly controlled (group II, 7.5% ≤ HbA 1c < 9.0%) glucose status, physicians prescribed predominantly the basal regimen (57.2% in group I and 54.6% in group II). In group I, no significant HbA 1c change was observed in any insulin regimen after 24 weeks of treatment. In all group II subgroups, the mean HbA 1c was decreased. The mean HbA 1c reduction was greatest in patients with a basal-bolus regimen and lowest in patients with a bolus regimen (aspart). However, there were no statistical differences in mean HbA 1c reduction among the four subgroups. In terms of target HbA 1c achievement, the proportion of patients achieving HbA 1c < 6.5% and < 7.0% was the greatest in patients with a basal-bolus regimen (11.3%) and bolus regimen (28.6%), respectively. In patients with a very poorly controlled glucose status (group III, HbA 1c > 9.0%), Korean physicians preferred both basal (46.3%) and biphasic (40.4%) insulin regimens. In group III, mean HbA 1c reduction was the greatest in patients with a basalbolus regimen (À3.50%) and lowest in patients with a bolus regimen (À1.81%; p < 0.001). With respect to the effectiveness of insulin analogues based on baseline HbA 1c levels, the glucoselowering effectiveness (À0.01% to 0.42% reduction in HbA 1c level) was minimal or equivalent in group I (HbA 1c < 7.5%, mean HbA 1c level of 6.8%). In addition, the percentage of patients reaching a target HbA 1c level of < 7.0% was not different among the four insulin regimens (23.8-36.8%). In the poorly controlled T2D group II patients (7.5% ≤ HbA 1c ≤ 9.0%, mean HbA 1c level of 8.3%), the HbA 1c reduction effectiveness was perceivable (À0.04% to À0.92% reduction in HbA 1c level). The percentage of patients reaching a target HbA 1c level of < 7.0% was significantly higher in the subgroup using bolus (28.6%) and basal-bolus (22.6%) regimens (p = 0.049). In the very poorly controlled T2D group III patients (HbA 1c > 9.0%, mean HbA 1c level of 11.0%), the HbA 1c reduction effectiveness was pronounced (À1.81% to À3.50% reduction in HbA 1c level). The percentage of patients reaching the target HbA 1c level of < 7.0% was not significantly different among the four subgroups (8.6-11.4%). Despite statistical insignificance, the basal-bolus regimen showed the highest percentage of patients reaching the target HbA 1c level of < 7.0% (11.4%). Regarding the use of basal-bolus regimen in clinical practice, except for the patients achieving the HbA 1c level of < 7.0% in group II, higher HbA 1c reduction effectiveness and higher percentages of Korean patients that achieved target HbA 1c levels < 6.5% or < 7.0% were found in the poorly or very poorly controlled T2D groups II and III, respectively.
Hypoglycaemic events and body weight change according to baseline HbA 1c levels
Although hypoglycaemic events were similar across the different insulin regimens in group I, hypoglycaemic events were most frequently observed in patients with basal-bolus regimen in group II (17.0%) and group III (14.0%; both p < 0.001). In terms of body weight change, treatment with basal-bolus or biphasic regimens showed greater weight gain compared with other insulin modalities in group III (p = 0.036); however, differences in body weight change were not observed in group I and II according to different insulin regimens. Next, we determined the best insulin modality allows patients to meet their glycemic goals while avoiding the risk of hypoglycaemia according to different insulin regimens. The percentage of patients reaching a target HbA 1c level of < 7.0% without hypoglycaemia was greater in patients on a bolus regimen in group II (25.7%). In group III, although statistically significant, the achievement of glycemic goals without hypoglycaemia was similar across the insulin regimens (Table 3) .
Discussion
Despite little controversy regarding the need for optimal glycemic control in insulin therapy for patients with poorly controlled diabetes (6-8), which insulin therapy treatment modality allows patients to best meet and maintain individualised glycemic goals while avoiding the risk of hypoglycaemia remains unclear (9) . Furthermore, most studies recommend the insulin therapy to be based on HbA 1c levels (6) (7) (8) . In terms of its non-randomised, non-interventional study design, the present study has both strengths and limitations that could be complemented by further investigations. Although randomised clinical trials are considered the gold standard, the non-interventional study design evaluates effectiveness and optimal regimens in real clinical practice (4, 10) . Based on a previous report (2), treatment with insulin analogues (aspart, biphasic aspart 30, detemir, or detemir and aspart) reduced HbA 1c , FPG and PPG levels during the 24-week of treatment period (1.6 AE 2.2%, 2.5 AE 4.7 and 4.0 AE 6.4 mmol/l, respectively).
To date, scientific reports investigating optimal approaches to treatment with insulin analogues and comparing their glucose-lowering effectiveness in real practice have been lacking in Korean patients with T2D. Therefore, we investigated current decisionmaking on the initiation of insulin analogues based on baseline HbA 1c levels and the effectiveness of insulin regimens based on reductions in HbA 1c , as well as the proportion of patients reaching target HbA 1c < 7.0%. By understanding daily practice settings, we hope to suggest the optimal insulin analogue-based glycemic control in Korean patients with T2D.
Regarding current decisions on the initiation of insulin analogues, approximately 88.5% of patients in this observational study initiated insulin analogue therapy with HbA 1c levels greater than 7.5% and a disease duration of approximately 10.0 years. According to the consensus statements of the American Diabetes Association and the European Association for the Study of Diabetes (11), insulin initiation is recommended when FPG levels are above 250 mg/dl, random glucose levels are above 300 mg/dl, or HbA 1c is above 10.0%. However, insulin could also be considered whenever HbA 1c is above 8.5% and patients are already receiving a treatment to achieve a more effective control. Considering the status of glycemic control determined by HbA 1c levels, current decisions on the initiation of insulin analogues are within limits of the consensus reached by the Korean medical practitioners. Because the underlying pathophysiological nature of T2D involves initially increased insulin resistance and decreased insulin secretion with ongoing progressive deterioration in pancreatic b-cell function and resulting in pancreatic islet exhaustion, which corresponds clinically with deteriorating hyperglycaemia (12) (13) (14) , early initiation of insulin therapy might be considered the optimal approach. In addition, because of T2D characteristics in the Korean population where secretory dysfunction of pancreatic b-cells is the major underlying pathophysiology for the development and aggravation of hyperglycaemia (12, 15, 16) , an insulin regimen advocating control of postprandial hyperglycaemia on an individual basis might be an important area of study in the Korean population (5).
This study had several limitations. First, this study was performed on Korean subjects and thus, determining the glucose-lowering effectiveness of insulin analogues and their combination in other ethnicities or study populations is necessary. Second, we did not consider the effect of other confounders potentially affecting glucose-lowering effectiveness and adverse effects of different insulin regimens, including age, gender, BMI, duration of diabetes and concomitant oral hypoglycaemic agents.
In summary, this observational study provides important information on how pharmaceutical insulin therapies perform in real clinical practice. Physicians might decide to start insulin therapy in patients with T2D if the HbA 1c level is greater than 7.5%. Based on our results, we suggest that a basalbolus regimen might be adquate in Korean patients with poorly controlled T2D (HbA 1c > 9.0%). A further large-scale, randomised, interventional study should be performed to clarify the effectiveness and safety of a basal-bolus regimen in Korean patients with T2D.
